Abstract
SLGT2 inhibitors (gliflozins) are a novel class of antidiabetics. Due to their mechanism of action, they are particularly suitable as a part of combination therapy in patients with type 2 diabetes mellitus.
They are characterised by high efficacy, low incidence of adverse events including hypoglycaemia and a favourable impact on blood pressure and body weight. According to the available data, in patients with diabetes and proper cardiac function gliflozins act as antidiabetics, whilst in patients with reduced cardiac reserve, or more precisely after a cardiac event, they lowerthe risk of the hospitalisation for heart failure or death particularly associated with heart failure.
Another important effect of gliflozins may be reducing the decline of glomerular filtration rate which could represent a significantstep forward the prevention and treatment of cardiorenal syndrome.